Skip to main content
. 2018 Aug 30;11(6):1292–1300. doi: 10.1016/j.tranon.2018.08.003

Figure 1.

Figure 1

HCMV-specific antibodies are elevated in patients with ovarian cancer and benign cystadenoma. (A) HCMV-IgM was detected in 4 (12%) patients with ovarian cancer patients and in 1 (3%) patient with benign cystadenoma, but not in healthy age-matched controls. (B) HCMV-IgG levels were significantly higher in patients with ovarian cancer (P = .002) and benign cystadenoma (P < .0001) than in age-matched healthy female blood donors who served as controls.